These results are very helpful in tracking the dynamic changes and mutation status of the cellular free DNA caused by the EGFR-TKI therapy and for further evaluating its correlation with the tumor burden in patients with advanced NSCLC MRD. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.